

Project Selection Committee - COVID-19

Alan E Winter, PhD, FCAE

Alan Winter was British Columbia's first Innovation Commissioner from 2018-2020.

He has wide experience at senior levels in the technology sector and in government, including such roles as the President and CEO of Genome British Columbia from 2001 to 2016, the founding President and CEO of the New Media Innovation Centre in Vancouver, the President of the ComDev Space Group in Ontario, and the President and CEO of MPR Teltech Ltd., at that time the largest technology company in Vancouver. During his tenure as CEO, six companies were spun out of MPR, including PMC-Sierra and Sierra Wireless. Prior to MPR he worked for Telesat Canada and the federal Communications Research Centre in Ottawa.

Dr Winter has been a director of over 30 organizations and companies. In 2007, he received a Leadership Award from Life Sciences BC (LSBC). In 2017 he received the Don Rix Award for Lifetime Achievement from LSBC and the Bill Thompson Lifetime Achievement Award from the BC TIA.

He received his Ph.D. from Queen's University at Kingston, Ontario and was recognized by the Queen's alumni Legacy of Achievement.

Dr. Catalina Lopez-Correa, Chief Operating Officer at Ruta N Medellin

With more than 20 years of international experience in both the academic and private sectors, Dr. Catalina Lopez-Correa's deep understanding of genomics and innovation has inspired leaders in science and industry to collaborate toward solving some of the world's greatest challenges.

Catalina is Chief Operating Officer at Ruta N Medellin. In this capacity, she is leading the operations of a world class innovation hub that uses cutting edge technologies and approaches to solve the city's most pressing social and economic challenges. With Ruta N, Catalina is supporting SMEs, universities and governmental initiatives aiming at putting innovation at the forefront of economic and social development. Prior to joining Ruta N, Catalina was the CSO and Vice-President Sectors at Genome British Columbia (2016-2019) and CSO and Vice-president Scientific Affaires at Genome Quebec (2008-2015), where she was instrumental in developing competitive teams for national and provincial research and innovation initiatives raising the profile of Canadian genomics on the global stage.

Before becoming one of Canada's leading advocates for genomics research and translation, and an international leader in using innovation to solve world challenges, Catalina held senior research positions with pharmaceutical giant Eli Lilly and the renowned deCODE genetics lab in Iceland. From leading teams to identifying genomic biomarkers in therapeutic areas of oncology, cardio-metabolic, and neurosciences to developing screening strategies associated with disease, Catalina's leadership helped drive the discovery and development pipelines.

As part of her commitment to international development, Catalina has championed several initiatives aimed at demonstrating the impact of genomics and innovation in developing countries, including a book on Genomics in Emerging Economies and several articles. Since 2002 she has served as evaluator for large multinational projects funded by the European Commission and has been recognized with several awards nationally and internationally.

Catalina holds a Medical degree from the UPB in Colombia, a Master's degree in Human Genetics from Paris V University in France, a PhD in Medical Sciences from the KULeuven in Belgium, and a mini MBA from McGill University in Canada.

Awards:

In 2017 she received the Canadian Senate 150th Anniversary Medal. In 2013 she was recognized by National Order of Merit Award in the Rank of Officer, appointed by the Honorable President of the Republic of Colombia. This honorable distinction is conferred to Dr. Lopez-Correa for her outstanding professional and academic career and the scientific contributions in the field of Genomics in Canada. In 2012 she was recognized as one of the 100 Colombians living abroad that have been highly successful on their professional career.

Dr Geoff Houlton

Dr Houlton qualified in medicine from Ninewells Medical School at the University of Dundee. Following residency training in anesthesiology he joined the pharmaceutical industry in the UK as a medical advisor in product development. He was recruited to Canada to lead the development of the Medical Affairs Department of Glaxo Canada Inc. now Glaxo SmithKline (GSK). In this capacity he reorganized and expanded the Department to coordinate the international product development activities initiated by Glaxo Group Research in the UK. During his tenure new functions including regulatory affairs, data analysis and medical communications were added to support both product development and the marketing and sales efforts of the Company.

The success of his corporate development activities enabled his transfer to venture capital with MDS Health Sciences, later MDS Capital Corporation. One of his roles was to assess new

technologies for potential investment. As one of the Entrepreneurs in Residence he was also seconded to individual companies to assist in managing the hands-on product development activities as well as complementing the corporate financing processes that enable successful financing of investments.

He was a Founding Partner, Director, Vice President and Chief Scientific Officer of BioCatalyst Yorkton Inc., a venture management company. This Company sourced early stage technologies and created the corporate entity to develop these into products for acquisition. Following this Dr. Houlton worked as a Health Sciences Analyst for a number of Canadian investment banks including: Octagon Capital, Loewen Ondaatje McCutcheon and Union Securities Capital Markets Group.

Dr. Houlton was appointed CEO and a Director of Heart Force Medical Inc. in 2009 to enable the continuing financing and development of a nascent medical technology based on algorithmic analysis of sub-audible (seismocardiograph) frequencies emanating through the chest from the heart. Despite the hostile financing environment the Company registered two products; an initial product was registered with Health Canada, the FDA and the European Regulatory Agency and a second was certified by Health Canada and marketed to Naturopathic Doctors. Recently the Company secured investment from private European investors that are focused on the development of a software as a service model, using seismocardiological signals, to assess the electromechanical performance of the heart for both clinicians and consumers.

Dr Houlton now provides mentoring, consulting and advisory services.

Sally Daub

Sally Daub is a technology entrepreneur, venture capitalist and CEO with experience in semiconductors, consumer electronics, healthcare, quantum computing and blockchain, making her an in-demand advisor and board member to both private and public companies in Silicon Valley and Toronto.

As Founder and Managing Partner of Pool Global Partners, Sally is investing in the next generation of deep tech innovation and supporting founders by sharing her expertise in founding, funding and scaling technology companies through her global network of partners and operators. With an emphasis on operational expertise and concept-to-commercialization strategy, Sally has guided numerous technology companies through successful investor exits and IPOs.

A frequent lecturer and guest speaker at universities and events around the world, Sally is also a Fellow at Creative Destruction Lab, a leading deep technology innovation pipeline and accelerator program, where she provides mentorship and advice to promising entrepreneurs.

Sally has been recognized with numerous awards, including CDL's Fellow of Year (2017), Women's Executive Network's Top 100 Most Powerful Women (2010, 2011, 2012, 2013) and inducted into WXN's Hall of Fame (2014). She is also a Registered U.S. and Canadian Patent Attorney and a Member of the Law Society of Upper Canada.

Doug Buchanan

For more than twenty years Doug Buchanan was Managing Director & CEO of BC Biomedical Laboratories Ltd. where he provided leadership to all functional areas of the practice, and led major changes in the organization including a significant streamlining of the management team, the introduction of a number of strategic improvements in leadership practices, several significant acquisitions, and the development of a new, leading-edge laboratory. Doug substantially strengthened the customer-culture of the organization which during his tenure was consistently ranked among the '50 Best Employers in Canada' (1st for three years in a row).

Following the purchase of BC Biomedical by LifeLabs in 2013, Doug joined the leadership team of the new combined organization as Senior Integration Officer to help bring the two organizations together as a single, coherent entity. Prior to his retirement in 2015, Doug was appointed Senior VP Office of Strategy Management, and helped to guide LifeLabs' leaders in refining the forward agenda for the enterprise. He continues to work on projects for the company among other clients.

Other stops along Mr. Buchanan's career journey have included Sandwell Engineering where he ran the organization's global consulting practice and The WATCOM Group, a software development company spun off from the University of Waterloo where Doug led all marketing and sales activities. As a Partner at Price Waterhouse Management Consultants for a major portion of his working life, he supported clients worldwide in strategic management, business competitiveness, market research and project feasibility assessment before moving to the firm's national headquarters to guide development and implementation of the first formal strategic plan for PW Canada.

Doug is educated in the sciences and business (B.Sc. Hon Physics, M.Sc. Biology, MBA), is an ICD.D (certified Director by the Institute of Corporate Directors) and enjoys helping organizations as a Board member:

- Commercialization Advisory Board, Life Sciences Institute UBC, Vancouver (2015 - 2019) – providing advice to early-stage enterprises and thought-leaders at the university
- Augurex Life Sciences Corp., Vancouver (2013 - present) – independent Board member bringing relevant industry experience to this promising enterprise

- Excelleris Technologies, Vancouver (2005 to 2015) – member of the founding team for this unique JV/collaboration of competitors
- Ainsworth Lumber, Vancouver (2005 - 2008) – worked with the other independent Directors to substantially refinance this multi-billion dollar enterprise
- Chirologix Pharmaceuticals Inc., Vancouver (2000 - 2001) – brought on by VC investors for a reality check - idea did not reach commercialization
- Ronald McDonald House, Vancouver (1995 - 2001) – as a volunteer Director, introduced and facilitated formal strategic planning for the House
- BC Biomedical Laboratories Ltd., Vancouver (1994 - 2013)

Doug loves the outdoors almost as much as he enjoys spending time with his family, and he's particularly crazy about his four grandsons – ages 7 to 13.

Tara McCarville, Principal, Brighton Group

Tara McCarville is Principal Consultant at Brighton Group, a health industries solutions firm. As the former National Health Industries Leader for PwC Canada, Tara was accountable for leading a national practice focused on improving quality and outcomes for government, hospital, healthtech/medtech, home/long term care, and private equity clients. In her role at Brighton, Tara is working with health industries clients in both the public and private sector with crisis management, growth strategy & value creation, operational transformation, and talent & leadership support.

With a professional background in healthcare, management consulting and telecom, Tara has over 18 years of experience providing senior leadership in the private, public and not for profit sectors. She is an experienced, senior health executive who translates complex strategy to high performing operations, while developing talented and accomplished individuals and teams. Tara has built a reputation as a skilled communicator, exceptional relationship builder and collaborative health sector leader.

Tara holds a Master of Public Administration (MPA) from the University of Victoria, a Bachelor of Arts, Honours (BAH) from Queen's University and an International Baccalaureate (IB) from the Lester B. Pearson United World College. She is a Certified Health Executive (CHE) and a Project Management Professional (PMP). Tara also has a certificate in Clinical Risk, Negligence & Claims Management in Health Care from Osgoode Hall.